Teva becomes latest to launch generic version of Prozac in the USA

2 August 2001

Following the recent decision by a US District Court judge in which EliLilly lost patent protection for the antidepressant Prozac (fluoxetine; Marketletter August 6), Israel's Teva Pharmaceuticals has become the most recent of several drugmakers to have received clearance from the US Food and Drug Administration to market generic versions of the drug.

Teva received FDA approval for fluoxetine oral solution (20mg per 5ml) last week and expects to launch the drug immediately. It received a 180-day period of market exclusivity for this formulation, which follows the previously-gained tentative approval from the FDA for 10mg fluoxetine tablets (Marketletter June 11).

Companies now shipping fluoxetine

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight